Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 13.15Bid: 13.00Ask: 13.35Change: 0.10 (+0.77%)Riser - Immupharma
Spread: 0.35Spread as %: 2.69%Open: 12.95High: 13.15Low: 12.95Yesterday’s Close: 13.05

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
13.15
Share Price SpacerBid
13.00
Share Price SpacerAsk
13.35
Share Price SpacerChange
0.77%0.10
Share Price SpacerVolume
218,566
Share Price SpacerOpen
12.95
Share Price SpacerHigh
13.15
Share Price SpacerLow
12.95
Share Price SpacerClose
13.05
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 139.47m £18.34m 10,000

52 Week High 193.00 52 Week High Date 4-JAN-2018
52 Week Low 12.00 52 Week Low Date 18-SEP-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
13 61,024 157,542 -2.768 -4.75 0.00 0.00


London South East Users info for Immupharma




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-Sep-18
09:49:03
13.2227
80,000
Buy* 
13.00
13.35
10.58k
Trade Type:
Ordinary

19-Sep-18
09:23:53
13.2227
3,705
Buy* 
13.00
13.35
489.90
Trade Type:
Ordinary

19-Sep-18
09:15:36
13.0245
7,700
Sell* 
13.00
13.35
1,003
Trade Type:
Ordinary




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>


TrekMadone
Posts: 607
Opinion:No Opinion
Price:13.15
RE: Corporate Strategy
Today 10:32
Thanks watchman. From Tim’s proactive interview he said there was no need for blinded, unblinded or placebos etc for the MAP. Not clear about pick and mix steroids though. Will have to look through the trial scope for that detail. Not my skill I must say as I’m more of a hobbyist investor.
http://www.proactiveinvestors.co.uk/companies/stocktube/10512/immupharma-firmly-committed-to-lupuzor-ahead-of-managed-access-programme-10512.html
Trek
Nolupus
Posts: 717
Opinion:No Opinion
Price:13.15
RE: Corporate Strategy
Today 10:26
My question is...Why no mention of Bryan, Garnier & Co. Limited in this morning's RNS ??

Reminder....

mmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company's Nominated Adviser and joint corporate broker.

Â

Tim McCarthy, Chairman of ImmuPharma, commented: "We welcome Bryan Garnier as Joint Broker. Bryan Garnier provides ImmuPharma with deep healthcare expertise and pan European broking capability, to support the Company as we progress towards commercialisation."
watchman.
Posts: 8
Opinion:No Opinion
Price:13.15
RE: Corporate Strategy
Today 10:22
Good to see you back in Trek, always found your posts informative and with a healthy dose of humour. Hopefully time will see this ease up bit by bit as we get some updates over the next couple of years from patients on the follow-on study & the MAP. EasyP raises a good point about China as I understand Asian's are one of the groups more susceptible to Lupus. Although I think this is probably going to be a 2 year slow and steady journey from here on in, with a bit of positive news about outcomes for this patient group you could easily see a Chinese pharma company step in and take a position at any time IMHO.

Also we now have realistic possibilities for some positive advancement of the Nucant & Ureka platforms. The big positive I'm taking away from the forward plan is it appears that they are happy with the funds they currently have available to deliver it over the next couple of years so no need for a fund-raising dilution and the current knockdown price so happy to hold and let it play out over the next 2 years.

The one thing I'd really like to know is what, if any, SOC or other drugs will be used alongside the MAP dosage. Would be a real game changer if they had some success without the use of steroids and other not so nice SOC treatments.

Best of luck
Retour_du_Renard
Posts: 3,344
Opinion:No Opinion
Price:13.15
RE: Corporate Strategy
Today 10:20
Trek - Pretty sure they have 2 more viewings this afternoon so it would be better if you put in the asking now.
TrekMadone
Posts: 607
Opinion:No Opinion
Price:13.15
RE: Corporate Strategy
Today 09:13
I must say I expected more of a reaction today now that we are with multiple estate agents. Trek.
View more share chat for Immupharma (IMM) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.